Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)

Phase 2 Recruiting 23 enrolled University of Utah Eli Lilly and Company · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this clinical trial is to learn if the drugs Pirtobrutinib and Rituximab are effective for the treatment of newly diagnosed marginal zone lymphoma.

Timeline

Start: 2025-02-20
Primary completion: 2031-12
Completion: 2032-12

Publications

Sharp J, Shana'ah AY, Voorhees TJ, Bond DA, Sawalha Y, Sigmund A, Hanel W, Sehgal L, Alinari L, Baiocchi R, Maddocks K, Jones D, Christian B, Epperla N. Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma. J Natl Compr Canc Netw. 2025 Jun 23;23(7):e257045. doi: 10.6004/jnccn.2025.7045.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pirtobrutinib	Other / unclassified	—	Oral
Subject	Rituximab	Monoclonal antibody	—	Intravenous

Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)

Summary

Timeline

Publications

Drugs

Indications